Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2017
Reporting Period: Specific event date of October 17, 2017.
Context: The filing discloses compensatory arrangements for certain officers under the Company's 2017 Equity Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation issuances.
Material Changes
The Board of Directors approved the issuance of restricted shares of Common Stock to two executive officers as compensation for work performed prior to the issuance date:
- John Gormally (CEO): 150,000 restricted shares.
- Gary Rauch (VP, Finance and Treasurer): 36,277 restricted shares.
Total shares issued in this transaction: 186,277.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items beyond the specific equity grant described.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2017 Equity Incentive Plan to assess remaining capacity.
- Review the vesting schedule and restrictions attached to the 186,277 shares issued.
- Confirm the fair market value of the shares on the issuance date for accounting and dilution analysis.
- Check subsequent filings for any changes in executive compensation or equity plan amendments.